Long-term survival of the juvenile lethal arginase-deficient mouse with AAV gene therapy

Molecular Therapy

Volumn 20, Issue 10, 2012, Pages 1844-1851

  Lee, Eun K ^a   Hu, Chuhong ^a   Bhargava, Ragini ^a   Rozengurt, Nora ^a   Stout, David ^a   Grody, Wayne W ^a   Cederbaum, Stephen D ^a,b   Lipshutz, Gerald S ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIA; ARGINASE; ARGININE; GLUTAMINE; PARVOVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; GENE DOSAGE; GENE EXPRESSION; GENOTYPE; HISTOLOGY; HYPERARGININEMIA; IMMUNOHISTOCHEMISTRY; JUVENILE ANIMAL; LIFESPAN; MALE; MOUSE; NEWBORN; NONHUMAN; OUTCOME ASSESSMENT; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; WESTERN BLOTTING;

ADENO-ASSOCIATED VIRUS; ANIMALIA; MURINAE; MUS;

EID: 84867020263     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.129     Document Type: Article

References (25)

1. Iyer, R, Jenkinson, C P, Vockley, JG, Kern, RM, Grody, WW and Cederbaum, S (1998). The human arginases and arginase defciency. J Inherit Metab Dis 21 Suppl 1: 86-100.
2. Jain-Ghai, S, Nagamani, SC, Blaser, S, Siriwardena, K and Feigenbaum, A (2011). Arginase I defciency: severe infantile presentation with hyperammonemia: more common than reported? Mol Genet Metab 104: 107-111.
3. Picker, JD, Puga, AC, Levy, HL, Marsden, D, Shih, VE, Degirolami, U et al. (2003). Arginase defciency with lethal neonatal expression: evidence for the glutamine hypothesis of cerebral edema. J Pediatr 142: 349-352.
4. Prasad, AN, Breen, JC, Ampola, MG and Rosman, NP (1997). Argininemia: a treatable genetic cause of progressive spastic diplegia simulating cerebral palsy: case reports and literature review. J Child Neurol 12: 301-309.
5. Oldham, MS, VanMeter, JW, Shattuck, KF, Cederbaum, SD and Gropman, AL (2010). Diffusion tensor imaging in arginase defciency reveals damage to corticospinal tracts. Pediatr Neurol 42: 49-52.
6. Vockley, JG, Jenkinson, CP, Shukla, H, Kern, RM, Grody, WW and Cederbaum, SD (1996). Cloning and characterization of the human type II arginase gene. Genomics 38: 118-123.
7. Iyer, RK, Yoo, PK, Kern, RM, Rozengurt, N, Tsoa, R, O'Brien, WE et al. (2002). Mouse model for human arginase defciency. Mol Cell Biol 22: 4491-4498.
8. Wang, Z, Zhu, T, Qiao, C, Zhou, L, Wang, B, Zhang, J et al. (2005). Adeno-associated virus serotype 8 effciently delivers genes to muscle and heart. Nat Biotechnol 23: 321-328.
9. Cunningham, SC, Dane, A P, Spinoulas, A, Logan, GJ and Alexander, IE (2008). Gene delivery to the juvenile mouse liver using AAV2/8 vectors. Mol Ther 16: 1081-1088.
10. Fausto, N and Campbell, JS (2003). The role of hepatocytes and oval cells in liver regeneration and repopulation. Mech Dev 120: 117-130.
11. Magami, Y, Azuma, T, Inokuchi, H, Kokuno, S, Moriyasu, F, Kawai, K et al. (2002). Cell proliferation and renewal of normal hepatocytes and bile duct cells in adult mouse liver. Liver 22: 419-425.
12. Gau, CL, Rosenblatt, RA, Cerullo, V, Lay, FD, Dow, AC, Livesay, J et al. (2009). Short-term correction of arginase defciency in a neonatal murine model with a helper-dependent adenoviral vector. Mol Ther 17: 1155-1163.
13. Jenkinson, CP, Grody, WW and Cederbaum, SD (1996). Comparative properties of arginases. Comp Biochem Physiol B, Biochem Mol Biol 114: 107-132.
14. Singh, R, Pervin, S, Karimi, A, Cederbaum, S and Chaudhuri, G (2000). Arginase activity in human breast cancer cell lines: N(omega)-hydroxy-L-arginine selectively inhibits cell proliferation and induces apoptosis in MDA-MB-468 cells. Cancer Res 60: 3305-3312.
15. Fan, X, Ang, A, Pollock-Barziv, SM, Dipchand, AI, Ruiz, P, Wilson, G et al. (2004). Donor-specifc B-cell tolerance after ABO-incompatible infant heart transplantation. Nat Med 10: 1227-1233.
16. West, LJ, Morris, PJ and Wood, KJ (1994). Neonatal induction of tolerance to cardiac allografts. Transplant Proc 26: 207-208.
17. West, LJ and Tao, K (2002). Acceptance of third-party cardiac but not skin allografts induced by neonatal exposure to semi-allogeneic lymphohematopoietic cells. Am J Transplant 2: 733-744.
18. Hu, C, Busuttil, RW and Lipshutz, GS (2010). RH10 provides superior transgene expression in mice when compared with natural AAV serotypes for neonatal gene therapy. J Gene Med 12: 766-778.
19. Hu, C, Cela, RG, Suzuki, M, Lee, B and Lipshutz, GS (2011). Neonatal helper-dependent adenoviral vector gene therapy mediates correction of hemophilia A and tolerance to human factor VIII. Proc Natl Acad Sci USA 108: 2082-2087.
20. Hu, C and Lipshutz, GS (2012). AAV-based neonatal gene therapy for hemophilia A: long-term correction and avoidance of immune responses in mice. Gene Ther.
21. Chandler, RJ and Venditti, CP (2010). Long-term rescue of a lethal murine model of methylmalonic acidemia using adeno-associated viral gene therapy. Mol Ther 18: 11-16.
22. Cunningham, SC, Spinoulas, A, Carpenter, KH, Wilcken, B, Kuchel, PW and Alexander, IE (2009). AAV2/8-mediated correction of OTC defciency is robust in adult but not neonatal Spf(ash) mice. Mol Ther 17: 1340-1346.
23. Cunningham, SC, Kok, CY, Dane, A P, Carpenter, K, Kizana, E, Kuchel, PW et al. (2011). Induction and prevention of severe hyperammonemia in the spfash mouse model of ornithine transcarbamylase defciency using shRNA and rAAV-mediated gene delivery. Mol Ther 19: 854-859.
24. Wang, L, Wang, H, Morizono, H, Bell, P, Jones, D, Lin, J et al. (2011). Sustained correction of OTC defciency in spf(ash) mice using optimized self-complementary AAV2/8 vectors. Gene Ther.
25. Suckow, C, Kuntner, C, Chow, P, Silverman, R, Chatziioannou, A and Stout, D (2009). Multimodality rodent imaging chambers for use under barrier conditions with gas anesthesia. Mol Imaging Biol 11: 100-106.